South Korea · Delayed Price · Currency is KRW Next Biomedical Statistics
Total Valuation
Next Biomedical has a market cap or net worth of KRW 267.36 billion. The enterprise value is 239.32 billion.
| Market Cap | 267.36B |
| Enterprise Value | 239.32B |
Important Dates
The next estimated earnings date is Friday, August 28, 2026.
| Earnings Date | Aug 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Next Biomedical has 8.28 million shares outstanding. The number of shares has increased by 2.72% in one year.
| Current Share Class | 8.28M |
| Shares Outstanding | 8.28M |
| Shares Change (YoY) | +2.72% |
| Shares Change (QoQ) | +0.22% |
| Owned by Insiders (%) | 31.26% |
| Owned by Institutions (%) | 5.71% |
| Float | 5.66M |
Valuation Ratios
The trailing PE ratio is 1,149.61.
| PE Ratio | 1,149.61 |
| Forward PE | n/a |
| PS Ratio | 15.03 |
| PB Ratio | 5.44 |
| P/TBV Ratio | 5.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 317.36 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 1,029.05 |
| EV / Sales | 13.45 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.02, with a Debt / Equity ratio of 0.14.
| Current Ratio | 5.02 |
| Quick Ratio | 4.46 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | -38.59 |
| Interest Coverage | -8.49 |
Financial Efficiency
Return on equity (ROE) is 0.49% and return on invested capital (ROIC) is -2.55%.
| Return on Equity (ROE) | 0.49% |
| Return on Assets (ROA) | -2.34% |
| Return on Invested Capital (ROIC) | -2.55% |
| Return on Capital Employed (ROCE) | -4.20% |
| Weighted Average Cost of Capital (WACC) | -0.04% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.29 |
| Inventory Turnover | 1.89 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.21% in the last 52 weeks. The beta is -0.79, so Next Biomedical's price volatility has been lower than the market average.
| Beta (5Y) | -0.79 |
| 52-Week Price Change | -44.21% |
| 50-Day Moving Average | 38,089.00 |
| 200-Day Moving Average | 61,900.00 |
| Relative Strength Index (RSI) | 41.72 |
| Average Volume (20 Days) | 35,188 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Next Biomedical had revenue of KRW 17.79 billion and earned 232.56 million in profits. Earnings per share was 28.46.
| Revenue | 17.79B |
| Gross Profit | 12.48B |
| Operating Income | -2.30B |
| Pretax Income | 232.56M |
| Net Income | 232.56M |
| EBITDA | -1.76B |
| EBIT | -2.30B |
| Earnings Per Share (EPS) | 28.46 |
Balance Sheet
The company has 34.99 billion in cash and 6.95 billion in debt, with a net cash position of 28.04 billion or 3,387.37 per share.
| Cash & Cash Equivalents | 34.99B |
| Total Debt | 6.95B |
| Net Cash | 28.04B |
| Net Cash Per Share | 3,387.37 |
| Equity (Book Value) | 49.16B |
| Book Value Per Share | 5,979.66 |
| Working Capital | 35.42B |
Cash Flow
In the last 12 months, operating cash flow was 842.43 million and capital expenditures -1.02 billion, giving a free cash flow of -180.14 million.
| Operating Cash Flow | 842.43M |
| Capital Expenditures | -1.02B |
| Depreciation & Amortization | 533.61M |
| Net Borrowing | -4.69B |
| Free Cash Flow | -180.14M |
| FCF Per Share | -21.76 |
Margins
Gross margin is 70.14%, with operating and profit margins of -12.92% and 1.31%.
| Gross Margin | 70.14% |
| Operating Margin | -12.92% |
| Pretax Margin | 1.31% |
| Profit Margin | 1.31% |
| EBITDA Margin | -9.92% |
| EBIT Margin | -12.92% |
| FCF Margin | n/a |
Dividends & Yields
Next Biomedical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.72% |
| Shareholder Yield | -2.72% |
| Earnings Yield | 0.09% |
| FCF Yield | -0.07% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Next Biomedical is 87,666.67, which is 163.66% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 87,666.67 |
| Price Target Difference | 163.66% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 48.90% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Next Biomedical has an Altman Z-Score of 21.44 and a Piotroski F-Score of 6.
| Altman Z-Score | 21.44 |
| Piotroski F-Score | 6 |